2022
DOI: 10.38159/gpj.2022101
|View full text |Cite
|
Sign up to set email alerts
|

Advancement of Tobacco Control in Ghana: Barriers & Opportunities – A Brief Situation Report

Abstract: Adequate tobacco control in the wake of the ongoing COVID-19 pandemic cannot be overemphasized. As a Lower Middle-Income Country (LMIC) with peculiar needs, Ghana can strengthen her tobacco control regime by advancing country-specific and resilient programmes. The Food and Drugs Authority (FDA) in partnership with WHO embarked on a national project to sensitize law enforcement officers on the existing tobacco control provisions whilst identifying control barriers peculiar to the various regional groupings. The… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 5 publications
0
1
0
Order By: Relevance
“…Exceptionally, the Rwanda Food and Drug Authority (FDA) in collaboration with the University of Rwanda published assessment results at ML2 and shared the challenges, hindering the implementation of key regulatory functions in their journey toward ML3 ( 50 ). In contrast, Ghana ( 58 ) and Tanzania ( 59 ) shared their knowledge and experience after achieving ML3. In emulating Rwanda FDA and the spirit of contributing to regulatory science, opening access to the GBT for academic and public health researchers would improve knowledge and experience sharing, regardless of the ML ( 10 ).…”
Section: Discussionmentioning
confidence: 99%
“…Exceptionally, the Rwanda Food and Drug Authority (FDA) in collaboration with the University of Rwanda published assessment results at ML2 and shared the challenges, hindering the implementation of key regulatory functions in their journey toward ML3 ( 50 ). In contrast, Ghana ( 58 ) and Tanzania ( 59 ) shared their knowledge and experience after achieving ML3. In emulating Rwanda FDA and the spirit of contributing to regulatory science, opening access to the GBT for academic and public health researchers would improve knowledge and experience sharing, regardless of the ML ( 10 ).…”
Section: Discussionmentioning
confidence: 99%